Treatment

Clinical Trials & Studies

Topaz- Actively Enrolling

A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion.

Ophthotech OPH2003 – Actively Enrolling

This a phase 2a study for fovea-sparing dry age related macular degeneration with unifocal or multifocal atrophy. It is studying intravitreal injections of a drug called Zimura by way of anti-complement C5 mechanism. This study started in January 2016 and the estimated completion date is April 2019.

 

ZIMURA – Enrollment Closed

To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD).

 

More information can be found here.

 

EyeArt – Enrollment Closed

More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommended for all diabetic patients since vision loss can be prevented with laser photocoagulation and anti-VEGF treatment if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is orders of magnitude smaller than that needed to screen the large, growing diabetic population. Therefore, to meet this large unmet need for DR screening, a fully-automated computerized DR screening system is necessary.

EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.

 

More information can be found here.

Ophthea – Actively Enrolling

A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.

More information can be found here.

 

Allergan Sequoia – Enrollment Closed

This is a phase 3 study for patients with treatment naive wet age related macular degeneration. This study is evaluating intravitreal abicipar (DARPin based anti-angiogenic drug), in comparison to intravitreal anti-VEGF ranibizmuab (Lucentis) injections. The estimated enrollment is 900 patients. The study started around June 2015, and will end around May 2019.

More information can be found here.

Panda

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration

More information can be found here.

Yosemite

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

More information can be found here.

Tenaya

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

More information can be found here.

Opthea DME

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

More information can be found here.

Senju

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

More information can be found here.

Merlin

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

More information can be found here.

 

If you would like to participate in our research program please contact our Research Coordinator at 

909-335-8938 or 

email: jsmith@vrsurgeons.com.

Riverside: 9041 Magnolia Ave, Suite 207

Redlands1895 Orange Tree Lane, Suite 204

Victorville15413 Anacapa Road, #6B

© 2020 by Retina Consultants of Southern California.  All rights reserved.  Privacy Statement.   DISCLAIMER